

## Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Michael C. d'Emden<sup>1,2</sup> · Alicia J. Jenkins<sup>4</sup> · Liping Li<sup>3</sup> · Diana Zannino<sup>3</sup> ·  
Kristy P. Mann<sup>3</sup> · James D. Best<sup>4</sup> · Bronwyn G. A. Stuckey<sup>5</sup> · Kris Park<sup>6</sup> ·  
Juha Saltevo<sup>7</sup> · Anthony C. Keech<sup>3</sup> · on behalf of the FIELD Study Investigators

Published online: 18 July 2015  
© Springer-Verlag Berlin Heidelberg 2015

**Erratum to: Diabetologia**  
**DOI 10.1007/s00125-014-3344-3**

The authors wish to point out two typographical errors in Fig. 3. In the fenofibrate arm, the proportion of men who had a stroke was 3.8% (not 13.8%) and the proportion of men who underwent revascularisation was 9.9% (not 39.9%). The plotted hazard ratios are correct.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-014-3344-3>.

---

✉ Anthony C. Keech  
fieldtrial@ctc.usyd.edu.au

<sup>1</sup> Endocrine Research Unit, Royal Brisbane Hospital, Brisbane, QLD, Australia

<sup>2</sup> Department of Medicine, University of Queensland, Brisbane, QLD, Australia

<sup>3</sup> National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia

<sup>4</sup> Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

<sup>5</sup> Keogh Institute for Medical Research and Sir Charles Gairdner Hospital, Perth, WA, Australia

<sup>6</sup> Nepean Hospital, Sydney, NSW, Australia

<sup>7</sup> Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland